The KeyNote-010 study was a randomized phase II/III study that compared treatment with pembrolizumab at 2 or 10 mg/kg Q3W versus docetaxel in 1034 patients with advanced NSCLC with positive PD-L1 expression (≥1%) progressing to at least a platinum-based CT regimen. This evidence concerns the gene CD274 and non-small cell lung carcinoma.